SBIR Phase I: Volition With An App

这个小企业创新研究（SBIR）第一阶段项目的更广泛的影响/商业潜力旨在通过为那些患有药物使用障碍（SUD）的人制作人工智能驱动的移动应用程序来减少美国过量死亡的人数。2018年，美国有超过6.7万例药物过量死亡。该项目有能力挽救生命，并减少每年用于治疗sud的7400亿美元，因此有可能改变现有的行为健康市场。任何拥有手机的人都可以免费使用这款应用程序，它使用人工智能（AI）专家系统，为有需要的人提供适当的循证恢复计划。纳入了医学上公认的基于应急的治疗过程，以帮助个人遵循他们的康复计划。小企业创新研究（SBIR）第一阶段项目将开发一个专家系统，为受SUD影响的个人制定基于证据的个性化康复计划。为此，该公司正在开发南德意志集团的自我导向恢复，同时通过一种新颖的、突出的奖励制度来增强合规性和激励。提高恢复计划遵从性是当前医疗保健行业功能的主要补充。该项目将利用一种积极的反馈循环，通过对药物使用障碍患者进行基于价值的新型支付，无论是否有临床医生的监督。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to decrease the number of overdose deaths in the U.S. by making an AI-driven mobile app to those suffering from substance use disorder (SUD). There were more than 67,000 drug overdose deaths in the U.S. in 2018. This project will potentially alter the existing behavioral health marketplace through its ability to save lives and reduce the $740 billion spent annually treating SUDs. The app, freely available to anyone with a mobile phone, uses an expert artificial intelligence (AI) system to suggest an appropriate evidence-based recovery plan to those in need. Medically recognized contingency-based therapy processes are incorporated to help individuals follow their recovery plans. This Small Business Innovation Research (SBIR) Phase I project will develop an expert system to develop an evidence-based personalized recovery program to individuals affected with SUD. To do this, the company is developing SUD self-directed recovery while enhancing compliance and motivation through a novel, salient reward system. Increasing recovery plan compliance is a major addition to current healthcare industry functions. The project will utilize a positive feedback loop via the novel use of value-based payment for individuals with substance use disorder with or without clinician oversight.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.